26th Jun 2008 10:56
VERNALIS PLC
ANNUAL INFORMATION UPDATE
As required under Prospectus Rule 5.2, and following publication of the Annual Report on 27th May 2008, the following summarises the information and documents published or made available to the public by the Company between 24th May 2007 and 26th June 2008 inclusive.
This Annual Information Update is also being made available on the Investors section of the Company's website at www.vernalis.com.
The information referred to in this Annual Information Update was correct at the time it was published but some information may now be out of date.
1. Announcements made via a Regulatory Information Service ("RIS")
Date |
Description of Contents of Announcement |
23/05/2007 |
AGM Statement |
04/06/2007 |
Director's Share Dealing |
06/06/2007 |
Director/PDMR Shareholding |
11/06/2007 |
Phase III Data demonstrates short term prevention treatment with Frova® reduces frequency and severity of menstrual migraine |
16/07/2007 |
Positive outcome of Phase IIa Trial of V3381 in diabetic neuropathic pain |
02/08/2007 |
Holdings(s) in Company |
07/08/2007 |
Annual Information Update |
17/08/2007 |
Update on Frova® - FDA requested extension of review date |
28/08/2007 |
Departure of Board Member |
03/09/2007 |
Milestone payment in Hsp90 inhibitor collaboration with Novartis |
10/09/2007 |
FDA advises new target action date on Frova® sNDA is 30 September 2007 |
10/09/2007 |
Notice of Results |
13/09/2007 |
Interim Results - Part 1 |
13/09/2007 |
Interim Results - Part 2 |
13/09/2007 |
Interim Results - Part 3 |
13/09/2007 |
Striking weight loss in Phase I Study V24343 in overweight and mildly obese volunteers |
01/10/2007 |
Action Letter from FDA on Frova® sNDA |
03/10/2007 |
Director/PDMR Shareholding |
04/10/2007 |
Director/PDMR Shareholding |
25/10/2007 |
Director/PDMR Shareholding |
12/11/2007 |
Director/PDMR Shareholding |
12/11/2007 |
Present at PJ Conference |
16/11/2007 |
Director/PDMR Shareholding |
21/12/2007 |
Payment of Deferred Consideration due under agreement for acquisition of Cita NeuroPharmaceuticals Inc and application for listing |
03/01/2008 |
Holding(s) in Company |
04/01/2008 |
Holding(s) in Company |
04/01/2008 |
Holding(s) in Company |
16/01/2008 |
Holding(s) in Company |
17/01/2008 |
Holding(s) in Company |
21/01/2008 |
Holding(s) in Company |
29/01/2008 |
Holding(s) in Company |
30/01/2008 |
Holding(s) in Company |
15/02/2008 |
Holding(s) in Company |
20/02/2008 |
Management Changes |
20/02/2008 |
Settlement of $56m Endo Loan and Major Business Restructuring |
08/04/2008 |
Update on Frova® sNDA |
21/04/2008 |
Paul Capital Healthcare €18.4m Financing Agreement |
21/04/2008 |
Notice of Results |
25/04/2008 |
Preliminary Results - Part 1 |
25/04/2008 |
Preliminary Results - Part 2 |
05/06/2008 |
Interim Management Statement for the Period 1 January 2008 to 5 June 2008 |
05/06/2008 |
Sale of Apokyn® and US Commercial Operations, Share Subscription and EGM |
06/06/2008 |
2007 Annual Report and Accounts and AGM Notification |
06/06/2008 |
Publication of Combined Circular and Prospectus |
26/06/2008 |
AGM Statement |
All of the above UK regulatory announcements have been made via a RIS and can be obtained from the London Stock Exchange's website at www.londonstockexchange.com or the Company's website at www.vernalis.com.
2. Documents filed at Companies House
All the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated.
Date |
Document Type |
25/05/2007 |
Annual Report and Accounts |
30/05/2007 |
Annual General Meeting Resolutions |
21/08/2007 |
Form 363s - Annual Return |
28/09/2007 |
Form 288b - Resignation of Director |
29/10/2007 |
Form 288c - Change of Particulars for Director |
01/02/2008 |
Form 88(2) - Return of Allotment of Shares |
07/03/2008 |
Form 288b - Resignation of Director |
Copies of the above documents, filed with the Registrar of Companies, can be obtained from the Companies House website at www.companieshouse.gov.uk, or can be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.
3. Documents published or sent to Shareholders or filed with the UK Listing Authority or submitted to the FSA
All the documents below were submitted to the FSA/UKLA on or around the dates indicated.
Date |
Document |
13/09/2007 |
Interim Report |
20/12/2007 |
Application for Admission of Securities to the Official List |
20/12/2007 |
Form 1 - Application for Admission of Securities to Trading |
25/04/2008 |
Preliminary Report |
27/05/2008 |
Annual Report, Notice of AGM and Consent Letter |
05/06/2008 |
Prospectus and Notice of EGM |
Certain documents submitted to the FSA can be viewed at the Document Viewing Facility situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.
The Notice of Annual General Meeting and Annual, Interim and Preliminary Reports are also available via the Investors section of the Company's website at www.vernalis.com.
4. Documents lodged with the Securities and Exchange Commission
The documents listed below were filed with the SEC on or around the dates indicated.
Date |
Document |
04/06/2007 |
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
04/06/2007 |
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
04/06/2007 |
Form 15F-12G - Securities registration termination of foreign private issuers [Section 12(g)] |
04/06/2007 |
Form F-6 POS - Post-effective amendments for immediately effective filing |
Copies of the above documents are available for viewing on the Securities and Exchange Commission website at www.sec.gov.
5. Further Information
Further information about Vernalis plc can be found on the Company's website at www.vernalis.com.
Related Shares:
Vernalis PLC